Orexo AB

ST:ORX Sweden Drug Manufacturers - Specialty & Generic
Market Cap
$73.47 Million
Skr824.25 Million SEK
Market Cap Rank
#21663 Global
#243 in Sweden
Share Price
Skr23.75
Change (1 day)
+1.71%
52-Week Range
Skr12.98 - Skr41.60
All Time High
Skr85.70
About

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company i… Read more

Orexo AB (ORX) - Total Liabilities

Latest total liabilities as of December 2025: Skr812.20 Million SEK

Based on the latest financial reports, Orexo AB (ORX) has total liabilities worth Skr812.20 Million SEK as of December 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Orexo AB - Total Liabilities Trend (2002–2025)

This chart illustrates how Orexo AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Orexo AB Competitors by Total Liabilities

The table below lists competitors of Orexo AB ranked by their total liabilities.

Liability Composition Analysis (2002–2025)

This chart breaks down Orexo AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.70 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.66 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.62 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Orexo AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Orexo AB (2002–2025)

The table below shows the annual total liabilities of Orexo AB from 2002 to 2025.

Year Total Liabilities Change
2025-12-31 Skr812.20 Million +12.63%
2024-12-31 Skr721.10 Million -0.91%
2023-12-31 Skr727.70 Million -20.48%
2022-12-31 Skr915.10 Million -0.97%
2021-12-31 Skr924.10 Million +37.03%
2020-12-31 Skr674.40 Million -15.14%
2019-12-31 Skr794.70 Million -1.96%
2018-12-31 Skr810.60 Million +20.12%
2017-12-31 Skr674.80 Million -4.76%
2016-12-31 Skr708.50 Million -5.51%
2015-12-31 Skr749.85 Million -2.73%
2014-12-31 Skr770.86 Million +26.19%
2013-12-31 Skr610.87 Million +110.24%
2012-12-31 Skr290.56 Million +23.64%
2011-12-31 Skr235.00 Million -3.87%
2010-12-31 Skr244.45 Million +142.82%
2009-12-31 Skr100.67 Million -23.87%
2008-12-31 Skr132.24 Million +1.24%
2007-12-31 Skr130.62 Million +135.01%
2006-12-31 Skr55.58 Million +71.54%
2005-12-31 Skr32.40 Million +21.90%
2004-12-31 Skr26.58 Million +186.74%
2003-12-31 Skr9.27 Million +19.91%
2002-12-31 Skr7.73 Million --